Eli Lilly and CompanyLLYNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank93
3Y CAGR+78.5%
5Y CAGR+25.7%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+78.5%/yr
Annual compound
5Y CAGR
+25.7%/yr
Recent acceleration
Percentile
P93
Near historical high
vs 5Y Ago
3.1x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 21.35% |
| 2024 | 18.01% |
| 2023 | 29.52% |
| 2022 | 3.75% |
| 2021 | 15.97% |
| 2020 | 6.82% |
| 2019 | 10.77% |
| 2018 | -0.88% |
| 2017 | -4.03% |
| 2016 | 10.71% |